SynthesisBMC ophthalmology2019
Efficacy and safety of interventions to control myopia progression in children: an overview of systematic reviews and meta-analyses.
Synthesis in BMC ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Pooled it
- Performance of artificial intelligence for the detection of pathological myopia from colour fundus images: a systematic review and meta-analysis.Eye (London, England) · 2024Pooled it
- Guidelines for preventing and slowing myopia progression in Brazilian children.Arquivos brasileiros de oftalmologia · 2024Guideline
- Control of myopia using orthokeratology lenses in Scandinavian children aged 6 to 12 years. Eighteen-month data from the Danish Randomized Study: Clinical study Of Near-sightedness; TReatment with Orthokeratology Lenses (CONTROL study).Acta ophthalmologica · 2022Trial
- Repeatability and inter-observer variation of choroidal thickness measurements using swept-source optical coherence tomography in myopic danish children aged 6-14 years.Acta ophthalmologica · 2022Trial
- Global research trends of myopia in children and adolescents: A bibliometric review with hotspot visualization.Medicine · 2026Review
- Management of myopia: a mini-review.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- Predicting onset of myopic refractive error in children using machine learning on routine pediatric eye examinations only.Scientific reports · 2025Article
- Standardized Corneal Topography-Driven AI for Orthokeratology Fitting: A Hybrid Deep/Machine Learning Approach With Enhanced Generalizability.Translational vision science & technology · 2025Article
- Childhood Myopia Part I: Contemporary Treatment Options.Investigative ophthalmology & visual science · 2025Review
- Topical review: Potential mechanisms of atropine for myopia control.Optometry and vision science : official publication of the American Academy of Optometry · 2025Review
- Research Tendency and Frontiers of Multifocal Lenses in Myopic Control in the Past Two Decades: A Bibliometric Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Comparison of two main orthokeratology lens designs in effectiveness and safety for myopia control in different ages.Frontiers in medicine · 2025Article
- Nomogram-based prediction of continued axial elongation in children undergoing orthokeratology.Frontiers in medicine · 2025Article
- Attitudes and knowledge of myopia management by Spanish optometrists.International ophthalmology · 2023Article
- Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia.The British journal of ophthalmology · 2023Review
- A cluster randomized trial of a comprehensive intervention nesting family and clinic into school centered implementation to reduce myopia and obesity among children and adolescents in Beijing, China: study protocol.BMC public health · 2023Article
- Prevention and management of childhood progressive myopia: National consensus guidelines.Indian journal of ophthalmology · 2023Article
- The alterations in ocular biometric parameters following short-term discontinuation of long-term orthokeratology and prior to subsequent lens fitting: a preliminary study.Annals of medicine · 2023Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundMyopia is a common visual disorder with increasing prevalence. Halting progression of myopia is critical, as high myopia can be complicated by a number of vision-compromising conditions.
methodsLiterature search was conducted in the following databases: Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE), Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE) and Centre for Reviews and Dissemination (CRD) Health Technology Assessment (HTA) database. Systematic reviews and meta-analyses investigating the efficacy and safety of multiple myopia interventions vs control conditions, were considered. Methodological quality and quality of evidence of eligible studies were assessed using the ROBIS tool and GRADE rating. The degree of overlapping of index publications in the eligible reviews was calculated with the corrected covered area (CCA).
resultsForty-four unique primary studies contained in 18 eligible reviews and involving 6400 children were included in the analysis. CCA was estimated as 6.2% and thus considered moderate. Results demonstrated the superior efficacy of atropine eyedrops; 1% atropine vs placebo (change in refraction: -0.78D, [- 1.30 to - 0.25] in 1 year), 0.025 to 0.05% atropine vs control (change in refraction: -0.51D, [- 0.60 to - 0.41] in 1 year), 0.01% atropine vs control (change in refraction: -0.50D, [- 0.76 to - 0.24] in 1 year). Atropine was followed by orthokeratology (axial elongation: - 0.19 mm, [- 0.21 to - 0.16] in 1 year) and novel multifocal soft contact lenses (change in refraction: -0.15D, [- 0.27 to - 0.03] in 1 year). As regards adverse events, 1% atropine induced blurred near vision (odds ratio [OR] 9.47, [1.17 to 76.78]) and hypersensitivity reactions (OR 8.91, [1.04 to 76.03]).
conclusionsExisting evidence has failed to convince doctors to uniformly embrace treatments for myopic progression control, possibly due to existence of some heterogeneity, reporting of side effects and lack of long-term follow-up. Research geared towards efficient interventions is still necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.